Antidepressant activity and calcium signaling cascades

Human Psychopharmacology

Volumn 16, Issue 1, 2001, Pages 71-80

  Halaris, Angelos ^a   Piletz, John E ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Calcium; Depression; N methyl D aspartate; Nitric oxide synthase

Indexed keywords

2 AMINO 4 PHOSPHONOMETHYL 3 HEPTENOIC ACID; 4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CALCIUM IONOPHORE; CALMODULIN; DOPAMINE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; GUANYLATE CYCLASE; IMIPRAMINE; KETAMINE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRITIUM; UNINDEXED DRUG; VOLTAGE GATED CHANNEL FORMING PROTEIN;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; BRAIN NERVE CELL; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITY; DEPRESSION; DRUG RESPONSE; DRUG SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MEMBRANE CHANNEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RODENT; STIMULATION;

EID: 0035107839     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.186     Document Type: Article

References (98)

1. Plasma and platelet excitatory amino acids in psychiatric disorders
2. Antidepressant effects of ketamine in depressed patients
3. Modulation of the AMPA receptor by phospholipase A2: Effect of the antidepressant trimipramine
4. Acute application of the tricyclic antidepressant desipramine presynaptically stimulates the exocytosis of glutamate in the hippocampus
5. Nitric oxide regulation of methamphetamine-induced dopamine release in caudate/putamen
6. Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate- and N-methyl-D-asparate-induced intracellular Ca2+ levels in neuronal culture
7. Clinical and biochemical aspects of depressive disorders - II. Transmitter/receptor theories
8. Alterations in cerebrospinal fluid and serum total calcium with changes in psychiatric state
9. Calcium: Bivalent cation in the bivalant psychoses
10. Calcium and electroconvulsive therapy in severe depressive illness
11. Monamine dysfunction and the pathophysiology and treatment of depression
12. Psychosis in hypoparathyroidism
13. Central nervous system manifestations of hyperparathyroidism
14. Dihydropyridine calcium channel antagonists as antidepressant drugs in mice and rats
15. Calcium antagonists in manic-depressive illness
16. Phenelzine-induced hypomania: Effect of verapamil
17. Increased platelet intracellular calcium concentration in patients with bipolar affective disorders
18. A molecular and cellular theory of depression
19. The effect of electro-convulsive therapy on spinal fluid constituents
20. Studies of mineral metabolism in mental depression. I. The effects of imipramine and electric convulsive therapy of calcium balance and kinetics
21. The role of the nitric oxide (NO) pathway in the discriminative stimuli of amphetamine and cocaine
22. Paroxetine is a novel nitric oxide synthase inhibitor
23. Calcium metabolism in states of depression
24. The impact of pharmacotherapy on psychiatric practice and research
25. The effects of electric convulsive treatments on nitrogen, calcium, and phosphorus
26. Effect of anti-depressant drugs on veratridine-evoked glutamate and aspartate release in rat prefrontal cortex
27. Study of calcium metabolism in electric convulsive therapy (ECT) in certain
28. Modulation of in vivo striatal transmitter release by nitric oxide and cyclic GMP
29. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test
30. Affective disorders and nitric oxide: A role in pathways to relapse and refractoriness?
31. CSF calcium: Clinical correlates in affective illness and schizophrenia
32. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 2. Chronic treatment results in downregulation of cortical β-adrenoceptors
33. The olfactory bulbectomized rat as a model of depression: An update
34. Effects of amitriptyline on serum glutamate and free tryptophan in rats
35. Increased serum glutamate in depressed patients
36. Activity of diltiazem and nifedipine in some animal models of depression
37. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715)
38. High serum and cerebrospial fluid Ca/Mg ratio in recently hospitalized acutely depressed patients
39. Involvement of nitric oxide in dopaminergic transmission in rat striatum: An in vivo electrochemical study
40. Calcium and magnesium concentrations in affective disorder: Difference between plasma and serum in relation to symptoms
41. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: Modulation by treatment with antidepressants and prediction of clinical responsivity
42. Hypotheses concerning the mechanism of action of antidepressant drugs
43. Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats
44. The effects of combined treatment with MK-801 and antidepressant drugs in the forced swimming test in rats
45. Central effects of repeated treatment with CGP 37849, a competitive NMDA receptor antagonist with potential antidepressant activity
46. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist
47. The effect of antidepressant drugs on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist
48. The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in the forced swimming test
49. Effects of MK-801 and antidepressant drugs in the forced swimming test in rats
50. Effects of dihydropyridine drugs on reversal by imipramine of helpless behavior in rats
51. Chronic effects of trimipramine, an antidepressant, on hippocampal synaptic plasticity
52. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment
53. Amitriptyline prevents N-methyl-D-asparate (NMDA)-induced toxicity, does not prevent NMDA-induced elevations of extracellular glutamate, but augments kainate-induced elevations of glutamate
54. Functional characterization of a heteromeric NMDA receptor channel from cloned cDNAs
55. Calcium and electroconvulsive therapy of depressed patients
56. Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats
57. Reduction of NMDA-induced behaviour after acute and chronic administration of desipramine in mice
58. Dihydropyridine calcium channel antagonists reduce immobility in the mouse behavioral despair teat; antidepressants facilitate nifedipine action
59. BAY K 8644 enhances immobility in the mouse behavioral despair test, an effect blocked by nifedipine
60. The L-arginine-nitric oxide pathway
61. Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex
62. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims
63. Swim stress increases the potency of glycine at the N-methyl-D-aspartate receptor complex
64. Adaptive changes in the N-methyl-D-asparate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid
65. Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors
66. A calcium hypothesis of antidepressant action
67. The effect of NMDA antagonists on footshock-induced fighting behavior in chronically stressed rats
68. On the slowness of action of tricyclic antidepressant drugs
69. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression
70. Effects of imipramine on serotonergic and beta-adrenergic receptor binding in a realistic animal model of depression
71. Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists
72. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine
73. Adaptation of the N-methyl-D-asparate receptor complex following chronic antidepressant treatments
74. Antidepressant treatment influences cyclic AMP accumulation induced by excitatory amino acids in rat brain
75. The influence of prolonged antidepressant treatment on the changes in cyclic AMP accumulation induced by excitatory amino acids in rat cerebral cortical slices
76. Effects of antidepressive agents on glutamatergic auto-regulatory presynaptic mechanism in the rat cerebral cortex
77. Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist
78. Calcium channel antagonists in mood disorders
79. Tricyclic antidepressants block N-methyl-D-aspartate receptors: Similarities to the action of zinc
80. Antidepressants: Beyond the synapse
81. Inescapable versus escapable shock modulates long-term potentiation in the rat
82. Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate
83. Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7-nitro indazole
84. Antidepressant for the new millennium
85. Chronic treatment with 1-aminocyclopropane-carboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-D-aspartate receptor complex
86. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression
87. The nitric oxide-cyclic GMP signalling pathway in rat brain
88. Problems with the current catechholamine hypothesis of antidepressant agents: Speculations leading to a new hypothesis
89. L-arginine induces dopamine release from the striatum in vivo
90. Functional NMDA antagonists: A new class of antidepressant agents
91. 1-amino-cyclopropanecarboxylic acid, a ligand of the strychnine-insensitive glycine receptor
92. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
93. 1-aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models
94. Effects of elevated calcium on learned helplessness and brain serotonin
95. Differential effects of electroconvulsive shock on the glutamate receptor mRNAs for NR2A, NR2B and mGluR5b
96. Rapid down-regulation of beta-adrenergic receptors evoked by combined forced swimming test and CGP 37849-a competitive antagonist of NMDA receptors
97. Effect of nitroprusside (nitric oxide) on endogenous dopamine release from rat striatal slices